Investigator Choice (IC) Chemotherapy

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals, Harbin Medical University

Conditions

Gastric Cancer or Gastroesophageal Junction AdenocarcinomaRecurrent or Metastatic, Platinum-refractory Cervical CancerSquamous Cell Carcinoma (SCC)

Phase 3

Study of Cemiplimab in Adults With Cervical Cancer

CompletedNCT03257267

Regeneron PharmaceuticalsRecurrent or Metastatic, Platinum-refractory Cervical Cancer, Squamous Cell Carcinoma (SCC)

Start: 2017-09-05End: 2023-04-20Updated: 2025-04-08

Unknown Phase

Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer

RecruitingNCT07552402

Harbin Medical UniversityGastric Cancer or Gastroesophageal Junction Adenocarcinoma

Start: 2026-06-10End: 2028-12-30Target: 150Updated: 2026-08-17

Related Papers

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer

CPT Pharmacometrics & Systems Pharmacology2022-10-1710 citations

EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.

2022-07-3124 citations

Survival with Cemiplimab in Recurrent Cervical Cancer

New England Journal of Medicine2022-02-09395 citations

Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

Journal of Clinical Oncology2021-12-21169 citations

164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

Cervical cancer2021-10-01

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts

Annals of Oncology2018-12-012 citations

Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts

Annals of Oncology2018-10-013 citations

GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase 3 trial of cemiplimab, an anti-PD-1, versus investigator's choice (IC) chemotherapy in ≥2 line recurrent or metastatic cervical cancer.

Journal of Clinical Oncology2018-05-206 citations